Japan Tightens Foreign Direct Investment Regulations on Life Science Companies
Prior notification requirements under the Japanese regulations were expanded to cover investments in life science companies.
On June 15, 2020, the Japanese government implemented new regulations that designate the manufacture of pharmaceuticals for infectious diseases and the manufacture of highly-controlled medical devices (medical devices that are classified as Class III or Class IV in Japan, such as a heart–lung machines and ventilators) as both "Designated Businesses" and "Core Businesses" under the Foreign Exchange and Foreign Trade Act of Japan ("FEFTA"). The new regulations were adopted in light of the COVID-19 pandemic, with the Japanese government increasingly focused on maintaining domestic production capabilities in key life science industries to protect national security and the health and safety of its people.
Under FEFTA, a foreign investor in a Japanese company is generally required to submit a notification to the government with respect to the acquisition of (i) one percent or more of the shares in a listed Japanese company or (ii) any shares in an unlisted Japanese company. However, if the target Japanese company includes a Designated Business, then the foreign investor must submit a notification prior to the acquisition and the acquisition will be subject to a 30-day waiting period, during which the government may review and raise objections to the planned investment. Moreover, while several exemptions to this prior notification requirement are available for passive investments in Designated Businesses, if the Designated Business is also classified as a Core Business, like the life science businesses at issue here, most of those exemptions will not apply.
These new regulations will apply to foreign direct investments that are made on or after July 15, 2020. As a result of the new regulations, many foreign investments in Japanese life science companies, even including passive investments, may be newly subject to the prior notification and review requirement under FEFTA, and potential investors should consider this regulation carefully before moving forward with any proposed investments in the Japanese life sciences sector.
Jones Day publications should not be construed as legal advice on any specific facts or circumstances. The contents are intended for general information purposes only and may not be quoted or referred to in any other publication or proceeding without the prior written consent of the Firm, to be given or withheld at our discretion. To request reprint permission for any of our publications, please use our “Contact Us” form, which can be found on our website at www.jonesday.com. The mailing of this publication is not intended to create, and receipt of it does not constitute, an attorney-client relationship. The views set forth herein are the personal views of the authors and do not necessarily reflect those of the Firm.